Profile your compound of interest, as single or combination therapies, in our OncoSignature™ HTRF drug discovery screening service to gain broader insight into clinical efficacy.
Leverage the proven capabilities of the OncoSignature™ platform, validated HTS workflow and expert data analysis to equip you with the quantitative data needed to elucidate underlying resistance and sensitivity mechanisms for effective patient stratification.
OncoSignatureTM HTRF Assay
Our HTRF assay allows for a large-scale exploration of underlying cellular mechanisms of drug response across a broad, clinically relevant panel of cancer cell line models. We utilize the highly sensitive and robust TR-FRET technology to rapidly screen your lead agents in a fully automated cell panel screening platform to interrogate your target protein of interest. We provide you with robust quantitative data across a broad panel of cell lines for a comprehensive insight into drug efficacy allowing you to drive key decisions throughout your drug development process.
Key advantages:
- Access to a clinically relevant panel of our 300 OncoSignature cancer cell lines
- Validated workflow and screen design for high-throughput execution to save you time and cost
- Over 350 HTRF kits available to study your target
- Evaluate your molecule of interest as a monotherapy or combination
- Continual screening cycle, flexible onboarding and compound submission
- Extensive internal in-house expertise (Cisbio-Revvity)
- Robust quantitative data and interpretation
What is the HTRF assay?
HTRF (Homogeneous Time Resolved Fluorescence) is a robust, specific and highly sensitive assay technology to measure analytes in a homogenous format, making it an ideal platform for high-throughput protein analysis in response to drug treatment. Compound screening in cell panel HTRF assays across multiple cancer types or specific molecular subtypes tests for the ability of your lead agents to modulate target protein activity or downstream signaling pathways implicated in cancer pathophysiology for a broader perspective on potential clinical efficacy.
Why use cell panel HTRF assay for drug discovery?
Understanding how and why different cancer types respond to therapy by studying the various molecular interactions and signaling pathways that underly mechanisms of cancer development and progression is crucial to designing effective therapeutics that ensure clinical translation. HTRF assays offer an avenue to studying key disease processes including GPCRs, kinases, epigenetics, protein-protein interactions and the quantification of a wide range of biomarkers and cytokines to understand your drugs therapeutic effect.
Main applications of OncoSignature™ HTRF Assay screening service
- Correlate inhibitor responses with underlying pathway activation
- Confirm MOA and on-target activity of single agents and novel combinations
- Better understand factors driving sensitivity and resistance for effective patient stratification
- Study drug effect on biomarkers associated with tumor growth and survival